 Verrica Pharmaceuticals Inc NASDAQ: VRCA was slapped with a third FDA rejection for YCANTH VP-102 as general contract manufacturing organization challenges continue to plague the approval. RBC Capital Markets has downgraded the stock to Sector Perform from Outperform. 